Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment of Individuals with Moderate-to-Severe COPD
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Redwood City, CA, May 13, 2013 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced the initiation of PINNACLE, a global Phase 3 program of PT003, the Company's fixed-dose combination of glycopyrrolate, a long-acting muscarinic antagonist (LAMA) and formoterol fumarate, a long-acting beta-2 agonist (LABA), delivered via a pressurized hydrofluoroalkane (HFA MDI) using the Company's novel co-suspension formulation platform. PINNACLE will assess the improvement in lung function generated by PT003 in individuals with moderate-to-severe COPD. Following the successful completion of this Phase 3 program, Pearl expects to file its US regulatory application in mid 2015, followed later by filings in the EU and Canada.
Help employers find you! Check out all the jobs and post your resume.
Redwood City, CA, May 13, 2013 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced the initiation of PINNACLE, a global Phase 3 program of PT003, the Company's fixed-dose combination of glycopyrrolate, a long-acting muscarinic antagonist (LAMA) and formoterol fumarate, a long-acting beta-2 agonist (LABA), delivered via a pressurized hydrofluoroalkane (HFA MDI) using the Company's novel co-suspension formulation platform. PINNACLE will assess the improvement in lung function generated by PT003 in individuals with moderate-to-severe COPD. Following the successful completion of this Phase 3 program, Pearl expects to file its US regulatory application in mid 2015, followed later by filings in the EU and Canada.
Help employers find you! Check out all the jobs and post your resume.